Lupin Gets USFDA Nod for Rivaroxaban Suspension; Share Price in Focus

On September 30, 2025, Lupin Limited announced 2 significant updates: regulatory approval from the USFDA for its Rivaroxaban oral suspension and the retirement of a senior executive. These developments underline both regulatory progress and leadership transition within the pharmaceutical major.

USFDA Approves Lupin’s Rivaroxaban Oral Suspension

Lupin received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Rivaroxaban for Oral Suspension, 1 mg/mL. The product is bioequivalent to Xarelto® by Janssen Pharmaceuticals and will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility.

Rivaroxaban is indicated for the treatment and prevention of venous thromboembolism (VTE) in paediatric patients and for thromboprophylaxis post-Fontan procedure in those aged 2 years and above. The drug recorded annual US sales of approximately $11 million as of July 2025.

Leadership Change: Retirement of Rajendra Chunodkar

Lupin also disclosed that Mr Rajendra Chunodkar, President - Manufacturing Operations and part of the senior management, has retired effective September 30, 2025. His departure marks the end of his tenure with Lupin, though no successor has been announced in the current release.

The disclosure complies with Regulation 30 of SEBI Listing Obligations and the Master Circular dated November 11, 2024. No further details on succession or interim management were shared.

Read More: Lupin Arm Ink Agreement to Acquire VISUfarma for €190 Million; Share Price Surges!

Lupin Share Price Performance

On October 1, 2025, Lupin share price opened at ₹1,917.40 on NSE, below the previous close of ₹1,933.20. During the day, it surged to ₹1,985.00 and dipped to ₹1,917.00. The stock is trading at ₹1,974.90 as of 11:52 AM. The stock registered a significant gain of 2.16%.

Over the past week, it has declined by 0.80%, over the past month, it has moved up by 4.51%, and over the past 3 months, it has moved up by 1.34%.

Conclusion

Lupin continues to strengthen its global pharmaceutical footprint with fresh regulatory wins like Rivaroxaban for Oral Suspension, while also managing leadership transitions at senior levels. These moves are likely to shape the company’s strategic direction as it enters the next phase of growth.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities are subject to market risks. Read all related documents carefully before investing.